Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Spectral Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Spectral Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Spectral Medical's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Spectral Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Spectral Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Spectral Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
Spectral Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Spectral Medical's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Spectral Medical's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Spectral Medical has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Paul M. Walker, MD, PhD, FRCS, has been the Chief Executive Officer and President of Spectral Medical Inc. since April 2001. Dr. Walker serves as the Chief Executive Officer and President of Sepsis, Inc. He served as the Chief Operating Officer of Toronto General Hospital. He served as a Surgeon in Chief and Vice President of the Surgical Directorate of the University Health Network in Toronto, Ontario. He joined Toronto Hospital in 1980 where he practised vascular surgery, critical-care medicine and ran a large research laboratory funded by the Medical Research Council of Canada from 1981 to 1997. He serves as the Chairman of HIO Group Incorporated. He has over 30 years of experience in Canadian healthcare — including as Surgeon-in-Chief and Chief Operating Officer of Toronto General Hospital. From 1990 to 1994, he was Program Director for Critical Care Medicine at the University of Toronto. Dr. Walker was an active vascular Surgeon, Director of the Intensive Care Program and Professor of Medicine and Laboratory Medicine at the University of Toronto. He has been a Director of Spectral Medical Inc. since April 2001. He served as a Director of Liponex Inc. since 2003 and served as a Member of its Scientific Advisory Board. He is the author of over 100 scientific publications. He was accredited as a general surgeon by the Royal College of Physicians and Surgeons of Canada in 1977 and as a vascular surgeon in 1984. Dr. Walker received his MD from the University of Western Ontario, London, Ontario in 1973. He is also a graduate of the Advanced Management Program of the Harvard School of Business in Cambridge, Massachusetts. He completed a PhD in Biochemistry at the University of Gothenburg (Sweden) in 1984.
Paul's compensation has increased whilst company is loss making.
Paul's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Spectral Medical management team is over 5 years, this suggests they are a seasoned and experienced team.
Vice President of Sales & Marketing
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Spectral Medical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Independent Chairman of the Board
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Spectral Medical individual insiders in the past 3 months.
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.